GLP-1 Providers Data & Contact Lists

The GLP-1 Providers Market

GLP-1 prescribing is the fastest-moving segment in healthcare. Demand for semaglutide and tirzepatide reshaped the entire weight-loss market between 2023 and 2026, and the prescriber base now spans traditional weight-loss clinics, med spas, primary care offices, and telehealth-first brands. The split between branded products like Wegovy and Zepbound and compounded versions is its own market within the market, and that line keeps moving as drug shortages resolve and FDA guidance on compounding tightens. New prescribers and new cash-pay brands enter every month, which is why no standing list stays accurate for long.

Where GLP-1 Providers Concentrate

GLP-1 prescribing concentrates where cash-pay demand and disposable income are highest, so affluent suburbs and Sun Belt metros lead on clinic and med-spa prescribers. Telehealth brands erase geography for a large share of scripts, serving the whole country from a handful of licensed states. That means state matters more for licensure and shipping rules than for patient density, and a national list has to reconcile both the local clinic footprint and the multi-state telehealth layer.

Who Controls GLP-1 Providers Purchasing Decisions

Who controls the decision depends entirely on the model. At a telehealth brand it is usually the clinical lead or the growth team, not the prescribing clinician. At a physician or NP-led clinic it is the owner, who is often also the prescriber. At a med spa offering GLP-1 as an add-on, the medical director signs off but the business owner decides what to stock. A list that names the prescribing NPI but not the person who controls purchasing wastes most of its value.

What Makes GLP-1 Providers Data Hard to Get Right

There is no GLP-1 prescriber taxonomy code, so these providers cannot be pulled by classification. The prescriber set changes weekly as clinics launch, add the service, or shut down. Providers span physicians, nurse practitioners, physician assistants, and telehealth brands that operate as LLCs separate from any individual NPI. Whether a provider dispenses branded or compounded product, which is the single most important attribute for many buyers, appears in no registry at all.

The Data Fields That Matter Most for GLP-1 Providers

The fields that matter most here go well beyond name and address. Buyers want the prescriber NPI and DEA status, whether the provider works in branded or compounded product, the practice model of clinic, med spa, primary care, or telehealth, the owner or medical-director contact, and the states the provider is licensed to treat in. Cash-pay versus insurance matters too, because the GLP-1 market is overwhelmingly cash-pay and that shapes how a clinic buys.

How Provyx Keeps GLP-1 Providers Data Current

What goes stale in this market is the prescriber list itself. Clinics launch, add or drop GLP-1, and shut down faster than any standing database can track, and a provider's branded-versus-compounded status can flip with a single guidance change. Provyx rebuilds each GLP-1 list against live sources when you order, so it reflects who is prescribing now rather than who was six months ago. That matters more here than in any other specialty, because a quarter-old list is already wrong.

Who Buys GLP-1 Providers Data

Compounding pharmacies are the most active buyers, building lists of cash-pay prescribing clinics to supply. Peptide and supplement companies target clinics for adjunct products. Telehealth-platform and clinic-software vendors reach fast-growing brands that have outgrown a basic stack. Nutrition, accountability-app, and lab-testing companies sell into GLP-1 programs as complementary services, and marketing agencies help clinics compete for patients in a crowded local market.

How Teams Use GLP-1 Providers Data

A compounding pharmacy uses the data to build a state-by-state list of cash-pay prescribing clinics and reach the owner before a competitor does. A supplement brand targets clinics that already run structured GLP-1 programs and would stock an adjunct product. A telehealth-software vendor reaches brands scaling past spreadsheets, and a lab company sells metabolic panels into clinics that monitor patients on therapy. In every case the value comes from current data, because last month's list already misses the newest entrants.

What Accurate GLP-1 Providers Data Is Worth

A current GLP-1 list is worth the supply relationships it locks in before competitors do. For a compounding pharmacy, reaching a new prescribing clinic first can mean an exclusive supply arrangement worth far more than the cost of the data. For an adjunct-product brand, a stale list means wasted outreach to clinics that no longer prescribe or never did. The economics favor accuracy because each correct, early contact in a fast-moving market compounds into recurring revenue.

Outreach That Works for GLP-1 Providers

Reach the owner or clinical lead by email and LinkedIn rather than a clinic's general inbox. Timing matters more here than in most specialties, because compounding rules and supply shift quarterly and a relevant message lands differently depending on where the market sits that month. Lead with supply reliability, compliance, or patient-acquisition economics, since these are cash-pay businesses that think in margins and volume. Generic blasts perform poorly with this audience because owners are inundated with supplier pitches.

When to Reach GLP-1 Providers

The best moment to reach a GLP-1 prescriber tracks the medication and compounding news cycle. When shortages ease or compounding guidance shifts, clinics reassess suppliers and program design, which opens the door for relevant outreach. New-clinic launches and the start of the calendar year, when patients restart weight goals, are also high-intent windows worth timing a campaign around.

Common Mistakes When Targeting GLP-1 Providers

The most common mistake is treating GLP-1 as one segment, when a telehealth brand, a med spa, and a primary-care clinic buy in completely different ways. The second is working from a stale list, because the prescriber set turns over faster than any annual database refresh. The third is ignoring branded-versus-compounded status, which determines whether a clinic is even a fit for a compounding pharmacy. The fourth is emailing the facility or LLC record instead of the person who decides.

The Bottom Line on GLP-1 Providers Data

If you sell into the GLP-1 market, treat the list as a live feed rather than a purchase. Decide first whether you are after clinic, med-spa, or telehealth prescribers, because they buy in different ways, then build against current sources and reach the owner or clinical lead directly. The clinics that matter most are the ones that opened last month, and only a built-on-demand list will have them.

How to Segment Your GLP-1 Providers List

• Model: clinic, med spa, primary care, telehealth brand
• Branded vs compounded product
• Prescriber type: MD, DO, NP, PA
• Cash-pay vs insurance
• State and multi-state coverage
• New launch vs established

Data Available for GLP-1 Providers

• Provider name and credentials
• NPI number and taxonomy code
• Practice name and address
• Direct email address
• Phone number (direct line where available)
• Practice size and type
• State license information

How It Works

1. Tell us what you need. Specify the glp-1 providers subtypes, geography, and any other filters for your target list.
2. We build your list. We pull matching records from our verified database and deliver a clean CSV or Excel file.
3. Start your outreach. Use the data for email campaigns, direct mail, phone outreach, or CRM enrichment.